Cart
Probiotics may improve insulin resistance, inflammation, and lipid profiles in type 2 diabetes

People with type 2 diabetes may develop a bacterial imbalance in the gut that can allow a type of toxin, LPS endotoxin, to leak into the bloodstream, creating systemic inflammation.

In this study, 61 adults with type 2 diabetes took a placebo or combined several probiotic strains of lactobacillus and bifidobacterium for a total of five-billion colony-forming-units per day. After six months, while the placebo group had not changed, those taking probiotics saw a nearly 70 percent decrease in circulating endotoxin levels compared to the start of the study. Also, several signs of inflammation: tumor necrosis factor alpha, interleukin-6, and C-reactive protein, declined between 53 and 77 percent.

The probiotics group also saw a 38 percent drop in glucose and insulin levels, and a 64 percent decrease in insulin resistance (HOMA-IR). Triglycerides declined 48 percent, total cholesterol dropped 19 percent, and the ratio of HDL, the “good” cholesterol, to total cholesterol, increased. Doctors said the significant improvements in insulin resistance, inflammation, and lipid profiles in type 2 diabetes suggest multi-strain probiotics may be an effective anti-diabetes therapy.

Previous Next Back to Top
More Related Articles